Current concepts and newer developments in the treatment of malignant gliomas

Indian Journal of Cancer

Volumn 46, Issue 2, 2009, Pages 88-95

  Omay, S B ^a   Vogelbaum, M A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Blood brain barrier; Chemotherapy; Convection enhanced delivery; Experimental therapy; Glioma; Radiation therapy; Surgery

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 6 O BENZYLGUANINE; ADENOVIRUS VECTOR; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CANCER VACCINE; CARMUSTINE; CINTREDEKIN BESUDOTOX; CP 673 451; CROSS REACTING MATERIAL 107; ERLOTINIB; GEFITINIB; IMATINIB; IRINOTECAN; LAPATINIB; LIPOSOME; LOMUSTINE; MONOCLONAL ANTIBODY; NITROSOUREA; PACLITAXEL; PLACEBO; PROCARBAZINE; PROTEIN TYROSINE KINASE INHIBITOR; TEMOZOLOMIDE; THYMIDINE KINASE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; VIRUS VECTOR;

ABSENCE OF SIDE EFFECTS; BONE MARROW SUPPRESSION; BRAIN TUMOR; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONFERENCE PAPER; CYTOLOGY; DRUG DELIVERY SYSTEM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RECEPTOR BINDING; GLIOBLASTOMA; HUMAN; INTERSTITIAL RADIATION; LIPOSOMAL GENE DELIVERY SYSTEM; MULTIPLE CYCLE TREATMENT; NONHUMAN; RADIOSURGERY; UNITED STATES;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRACHYTHERAPY; BRAIN NEOPLASMS; DACARBAZINE; GENE THERAPY; GLIOMA; HUMANS; IMMUNOTHERAPY; RADIOSURGERY; SIGNAL TRANSDUCTION;

EID: 64749085291     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.49146     Document Type: Conference Paper

References (81)

1. CBTRUS Statistical Report, Central Brain Tumor Registry of the United States 2004: Primary Brain Tumors in the United States, 1997-2001.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. Engl J Med 2005;352:987-96.
3. Avgeropoulos NG, Batchelor TT. New treatment strategies for malignant gliomas. Oncologist 1999;4:209-24.
4. Huncharek M, Muscat J. Treatment of recurrent high grade astrocytoma: Results of a systematic review of 1415 patients. Anticancer Res 1998;18:1303-11.
5. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurg 2001;95:190-8.
6. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 1983;52:997-1007.
7. Liang BC, Thornton AF Jr, Sandler HM, Greenberg HS. Malignant astrocytomas: Focal tumor recurrence after focal external beam radiation therapy. J Neurosurg 1991;75:559-63.
8. Sathornsumetee S, Rich JN. New approaches to primary brain tumor treatment. Anticancer Drugs 2006;17:1003-16.
9. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
10. Taphoorn MJ, Stupp R, Coens C, Osoba D, Kortmann R, van den Bent MJ, et al. Health-related quality of life in patients with glioblastoma: A randomised controlled trial. Lancet Oncol 2005;6:937-44.
11. Dinapoli RP, Brown LD, Arusell RM, Earle JD, O'Fallon JR, Buckner JC, et al. Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma. J Clin Oncol 1993;11:1316-21.
12. Black PM. Brain tumors. Part 1. N Engl J Med 1991;324:1471-6.
13. Shapiro WR, Green SB, Burger PC, Mahaley MS Jr, Selker RG, VanGilder JC, et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma: Brain Tumor Cooperative Group Trial 8001. J Neurosurg 1989;71:1-9.
14. Grossman SA, Batara JF. Current management of glioblastoma multiforme. Semin Oncol 2004;31:635-44.
15. Keles GE, Lamborn KR, Chang SM, Prados MD, Berger MS. Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. J Neurosurg 2004;100:41-6.
16. Barker FG 2nd, Chang SM, Gutin PH, Malec MK, McDermott MW, Prados MD, et al. Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 1998;42:709-20.
17. Norden AD, Wen PY. Glioma therapy in adults. Neurologist 2006;12:279-92.
18. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: A cooperative clinical trial. J Neurosurg 1978;49:333-43.
19. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980;30:907-11.
20. Wallner KE, Galicich JH, Krol G, Arbit E, Malkin MG. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 1989;16:1405-9.
21. Choucair AK, Levin VA, Gutin PH, Davis RL, Silver P, Edwards MS, et al. Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. J Neurosurg 1986;65:654-8.
22. Batchelor T, Supko JG. Experimental treatment approaches for malignant gliomas. In: Rose BD, editor. UpToDate, Waltham, MA; 2008.
23. Liang BC, Thornton AF Jr, Sandler HM, Greenberg HS. Malignant astrocytomas: Focal tumor recurrence after focal external beam radiation therapy. J Neurosurg 1991;75:559-63.
24. Narayana A, Yamada J, Berry S, Shah P, Hunt M, Gutin PH, et al. Intensity-modulated radiotherapy in high-grade gliomas: Clinical and dosimetric results. Int J Radiat Oncol Biol Phys 2006;64:892-7.
25. Tsao MN, Mehta MP, Whelan TJ, Morris DE, Hayman JA, Flickinger JC, et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. Int J Radiat Oncol Biol Phys 2005;63:47-55.
26. Sneed PK, Lamborn KR, Larson DA, Prados MD, Malec MK, McDermott MW, et al. Demonstration of brachytherapy boost doseresponse relationships in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1996;35:37-44.
27. Selker RG, Shapiro WR, Burger P, Blackwood MS, Arena VC, Gilder JC, et al. The Brain Tumor Cooperative Group NIH Trial 87-01: A randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 2002;51:343-55; discussion 355-7.
28. Huncharek M, Muscat J, Geschwind JF. Multi-drug versus single agent chemotherapy for high grade astrocytoma: Results of a metaanalysis. Anticancer Res 1998;18:4693-7.
29. Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: Recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 2006;24:2563-9.
30. Reardon DA, Wen PY. Therapeutic advances in the treatment of glioblastoma: Rationale and potential role of targeted agents. Oncologist 2006;11:152-64.
31. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 2002;20:2388-99.
32. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and beneft from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
33. Friedman HS, Kokkinakis DM, Pluda J, Friedman AH, Cokgor I, Haglund MM, et al. Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol 1998;16:3570-5.
34. Friedman HS, Pluda J, Quinn JA, Ewesuedo RB, Long L, Friedman AH, et al. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 2000;18:3522-8.
35. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas: The Polymer-brain Tumor Treatment Group. Lancet 1995;345:1008-12.
36. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003;5:79-88.
37. Jendrossek V, Belka C, Bamberg M. Novel chemotherapeutic agents for the treatment of glioblastoma multiforme. Expert Opin Investig Drugs 2003;12:1899-924 7.
38. Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 2001;8:83-96.
39. Benjamin R, Capparella J, Brown A. Classifcation of glioblastoma multiforme in adults by molecular genetics. Cancer J 2003;9:82-90.
40. Kesari S, Ramakrishna N, Sauvageot C, Stiles CD, Wen PY. Targeted molecular therapy of malignant gliomas. Curr Neurol Neurosci Rep 2005;5:186-97.
41. Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffer JS, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000;18:708-15.
42. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, et al. Phase II trial of geftinib in recurrent glioblastoma. J Clin Oncol 2004;22:133-42.
43. Lieberman FS, Cloughesy T, Fine H, et al. NABTC phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas. J Clin Oncol 2004;22:1510.
44. Haas-Kojan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 2005;97:880-7.
45. Kunwar S, Westphal M, Medhorn M, Ram Z, Sampson J, Byrne R, et al. Results From Precise: A Randomized Phase 3 Study In Patients With First Recurrent Glioblastoma Mulitforme (GBM) Comparing Cintredekin Besudotox (CB) Administered Via Convection-Enhanced Delivery (Ced) With Gliadel Wafers (GW). Abstracts for the Twelfth Annual Meeting of the Society for Neuro-Oncology (SNO). November 15 -18, 2007
46. Spector NL, Xia W, Burris H 3rd, Hurwitz H, Dees EC, Dowlati A, et al. Study of the biological effects of lapatinib: A reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005;23:2502-12.
47. Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, et al. AEE788: A dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 2004;64:4931-41.
48. Raymond E, Brandes A, Van Oosterom A. Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: An EORTC: NDDG/BTG Intergroup Study. J Clin Oncol 2004;22:1501.
49. Holdhoff M, Kreuzer KA, Appelt C, Scholz R, Na IK, Hildebrandt B, et al. Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. Blood Cells Mol Dis 2005;34:181-5.
50. Roberts WG, Whalen PM, Soderstrome E, Moraski G, Lyssikatos JP, Wang HF, et al. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673. Cancer Res 2005;65:957-66.
51. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
52. Solomon SD, McMurray JJ, Pfeffer MA,Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl JMed 2005;352:1071-80.
53. Tuettenberg J, Friedel C, Vajkoczy P. Angiogenesis in malignant glioma: A target for antitumor therapy? Crit Rev Oncol Hematol 2006;59:181-93.
54. Bello L, Carrabba G, Giussani C, Lucini V, Cerutti F, Scaglione F, et al. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 2001;61:7501-6.
55. Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, et al. Combined inhibition ofVEGFand PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004;18:338-40.
56. Farhadi MR, Capelle HH, Erber R, Ullrich A, Vajkoczy P. Combined inhibition of vascular endothelial growth factor and platelet-derived growth factor signaling: Effects on the angiogenesis, microcirculation, and growth of orthotopic malignant gliomas. J Neurosurg 2005;102:363-70.
57. Reardon DA, Quinn JA, Vredenburgh JJ, Gururangan S, Friedman AH, Desjardins A, et al. Phase 1 trial of geftinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res 2006;12:860-8.
58. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722-9.
59. Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fuorothymidine positron emission tomography: A pilot study. J Clin Oncol 2007;25:4714-21.
60. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, et al. Friedman bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722-9.
61. Hockaday DC, Shen S, Fiveash J, Raubitschek A, Colcher D, Liu A, et al. Imaging glioma extent with 131I-TM-601. J Nucl Med 2005;46:580-6.
62. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 2002;20:1389-97.
63. Wheeler CJ, Das A, Liu G, Yu JS, Black KL. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 2004;10:5316-26.
64. Yu JS, Luptrawan A, Black KL, Liu G. Mahaley Clinical Research Award: Chemosensitization of glioma through dendritic cell vaccination. Clin Neurosurg 2006;53:345-51.
65. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, et al. Molecular determinants of the response ofglioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012-24.
66. Cavaliere R, Wen PY, Schiff D. Novel therapies for malignant gliomas. Neurol Clin 2007;25:1141-71.
67. Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, et al. Epidermal growth factor receptor VIII peptide vaccination is effcacious against established intracerebral tumors. Clin Cancer Res 2003;9:4247-54.
68. Hussain AE, Blakley BW, Nicolas M, Balderston J. Assessment of the protective effects of amifostine against cisplatin-induced toxicity. J Otolaryngol 2003;32:294-7.
69. Pulkkanen KJ, Herttuala SY. Gene therapy for malignant glioma: Current clinical status. Mole Ther 2005;12:4.
70. Wood MJ, Byrnes AP, Pfaff DW, Rabkin SD, Charlton HM. Infammatory effects of gene transfer into the CNS with defective HSV-1 vectors. Gene Ther 1994;1:283-91.
71. Thomas CE, Schiedner G, Kochanek S, Castro MG, Löwenstein PR. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with firstgeneration, but not with highcapacity, adenovirus vectors: Toward realistic long-term neurological gene therapy for chronic diseases. Proc Natl Acad Sci U S A 2000;97:7482-7.
72. Dewey RA, Morrissey G, Cowsill CM, Stone D, Bolognani F, Dodd NJ, et al. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials. Nat Med 1999;5:1256-63.
73. Zermansky AJ, Bolognani F, Stone D, Cowsill CM, Morrissey G, Castro MG, et al. Towards global and long-term neurological gene therapy: Unexpected transgene dependent, high-level, and widespread distribution of HSV-1 thymidine kinase throughout the CNS. Mol Ther 2001;4:490-8.
74. Flawers A, Levin V. Chemotherapy for brain tumors. In: Kaye H, Laws ER, editors. Brain Tumors. New York: Churchill Livingstone; 2001.
75. Leary SP, Liu CY, Apuzzo ML. Toward the emergence of nanoneurosurgery: Part III-nanomedic?ne: Targeted nanotherapy, nanosurgery and progress toward the realization of nanoneurosurgery. Neurosurgery 2006;58:1009-26.
76. Raghavan R, Brady ML, Rodríguez-Ponce MI, Hartlep A, Pedain C, Sampson JH. Convection-enhanced delivery of therapeutics for brain disease and its optimization. Neurosurg Focus 2006;20:E12.
77. Huynh GH, Deen DF, Szoka FC Jr. Barriers to carrier mediated drug and gene delivery to brain tumors. J Control Release 2006;110:236-59.
78. MacKay JA, Deen DF, Szoka FC Jr. Distribution in brain of liposomes after convection enhanced delivery: Modulation by particle charge, particle diameter, and presence of steric coating, Brain Res 2005;1035:129-53.
79. Vogelbaum MA. Convection enhanced delivery for the treatment of malignant gliomas: Symposium review. J Neurooncol 2005;73:57-69.
80. Lidar Z, Mardor Y, Jonas T, Pfeffer R, Faibel M, Nass D, et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: A phase I/II clinical study. J Neurosurg 2004;100:472-930.
81. Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 2003;65:3-13.